TauRx Therapeutics Management Ltd (company statement), 2025-10-01: Company statement dated 1 October 2025 confirming that the UK MHRA has not decided the marketing application for HMTM and has asked for further information; no UK authorisation exists.
it requires some further information before a final determination on the suitability of hydromethylthionine mesylate (HMTM), as a potential oral treatment for Alzheimer’s disease, can be reached
TauRx Therapeutics Management Ltd (company statement), 2025-10-01: Company statement dated 1 October 2025 confirming that the UK MHRA has not decided the marketing application for HMTM and has asked for further information; no UK authorisation exists. Regulatory-status row. Timeline established from the company's own pages: UK MAA submitted 1 July 2024 (BusinessWire/TauRx release); MHRA request for further information received by 31 December 2024, company response due late February 2025; responses finalised 4 June 2025; this statement 1 October 2025 says a further information request is still outstanding. No MHRA marketing authorisation, FDA approval or EMA authorisation for HMTM/methylthioninium was found as of 2026-11-21 – no approval found. URL note: the company's /news/industry-news/ path 301-redirects to the /insights/industry-news/ path recorded here, which was opened. Also filed as MTK-24 (claims C3, F1).
